Top Story

Abnormalities related to C. gattii may be slow to resolve

March 3, 2015

Resolution of cryptococcomas and serum antigenemia related to Cryptococcus gattii infection was slow among patients, but late onset of treatment failure or relapse was uncommon, researchers from Canada reported, suggesting that treatment beyond recommended duration was unnecessary.

Peter Phillips, MD, of the division of infectious diseases at St. Paul’s Hospital in Vancouver, British Columbia, and colleagues reviewed medical records of 152 patients identified through surveillance and reported to the British Columbia Centre for Disease Control from 1999 through 2007. They analyzed risk factors for C. gattii mortality, as well as patterns in serum cryptococcal antigen (SCrAg) titers and the probability of developing chest cryptococcomas.

Allison Kempe In the Journals

Parent-requested delays in pediatric vaccinations require intervention

March 2, 2015
Many pediatricians and family physicians report receiving parental requests to spread out children’s immunization schedules, and despite concerns, agree to do so…
Meeting News Coverage

Survival benefit of 9.2 million life-years attributed to Brazilian ART program

March 2, 2015
SEATTLE — Universal ART offered in Brazil from 1997 to 2014 is estimated to have a population survival benefit of 9.2 million life-years, according to data presented…
Meeting News Coverage

Average cost per SVR12 was $171,000 for Olysio, Sovaldi regimens

March 2, 2015
SEATTLE — The mean cost per sustained virologic response at 12 weeks among a cohort of patients with hepatitis C virus infection receiving treatment with Olysio…
Meeting News Coverage

Patients with HIV play key role in TB transmission

March 2, 2015
SEATTLE — In contrast to previous hypotheses, HIV-positive patients with pulmonary tuberculosis appear to have an important function in the onward transmission…
More News Headlines »
CME
j526

Regimen Selection in HIV: Considering New Options to Optimize Outcomes

This activity is supported by an educational grant from Gilead Sciences Medical Affairs.

More than two decades into the antiretroviral therapy (ART) era, there are numerous options for HIV treatment. The goal…
More »
Meeting News Coverage Video
thumbnail for video 4083320513001

Video: Highlights in cancer and HIV treatments at CROI 2015

February 27, 2015
Infectious Disease News Editorial Board member Paul Volberding, MD, reviews HIV and cancer treatment data presented…
More »
CME
HCV Consults: Volume 1, Number 3

HCV Consults: Volume 1, Number 3

This activity is supported by educational grants from AbbVie and Genentech, Inc.

More »
morganatic-roan